Incyte Genomics INCY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Incyte Genomics (INCY) Business Model and Operations Summary
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Key Insights
Incyte Genomics (INCY) Core Market Data and Business Metrics
Latest Closing Price
$60.91Market Cap
$11.75 BillionPrice-Earnings Ratio
676.78Total Outstanding Shares
193.52 Million SharesTotal Employees
2,617Dividend
No dividendIPO Date
November 3, 1993SIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
NASDAQHeadquarters
1801 Augustine Cut-off, Wilmington, DE, 19803
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-1.92 Billion |
| Net Cash Flow From Financing Activities | $-2.04 Billion |
| Net Cash Flow From Operating Activities, Continuing | $101.85 Million |
| Net Cash Flow From Investing Activities, Continuing | $24.48 Million |
| Net Cash Flow From Investing Activities | $24.48 Million |
| Exchange Gains/Losses | $-7.84 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $4.08 Billion |
| Costs And Expenses | $4.13 Billion |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Diluted Earnings Per Share | $0.09 |
| Income/Loss From Continuing Operations After Tax | $32.48 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $43.77 Million |
| Other Comprehensive Income/Loss | $117.74 Million |
| Comprehensive Income/Loss Attributable To Parent | $25.24 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $-7.24 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $5.01 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Assets | $2.74 Billion |
| Noncurrent Liabilities | $339.56 Million |
| Noncurrent Assets | $2.20 Billion |
| Other Current Liabilities | $1.17 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||